Multiple Endocrine Neoplasia

Table of Contents

  1. What MEN Syndromes Are
  2. MEN1 — Wermer's Syndrome
  3. MEN2A — Sipple's Syndrome
  4. MEN2B — Most Aggressive Form
  5. MEN4 and Other Variants
  6. Genetic Testing and Counseling
  7. Screening Protocols
  8. Treatment and Surgical Principles
  9. Research Papers
  10. Connections
  11. Featured Videos

What MEN Syndromes Are

Multiple Endocrine Neoplasia (MEN) syndromes are a family of rare hereditary disorders in which tumors develop in two or more endocrine glands simultaneously or sequentially over a lifetime. Unlike sporadic endocrine tumors that arise by chance, MEN syndromes are caused by germline mutations — inherited changes in the DNA present in every cell of the body from birth — that dramatically increase the lifetime risk of tumor formation in specific glands.

Four recognized syndromes exist: MEN1, MEN2A, MEN2B, and MEN4. Each is caused by a distinct gene mutation and involves a characteristic pattern of affected glands. All four follow an autosomal dominant inheritance pattern, meaning that inheriting just one defective copy of the causative gene from either parent is sufficient to confer the syndrome. Each child of an affected parent has a 50% chance of inheriting the mutation.

The clinical significance of recognizing MEN syndromes extends far beyond treating the individual patient. Because the same germline mutation is shared among family members, a single diagnosis triggers a cascade of genetic testing, lifelong surveillance, and potentially preventive surgery for first-degree relatives — siblings, children, and parents — who may harbor the same mutation but have no symptoms yet. Early detection through biochemical screening routinely identifies tumors at a curable stage, before the aggressive spread that can occur if MEN is diagnosed only when symptoms appear.

The unifying biology across MEN syndromes is a defect in a gene that normally restrains cell growth in endocrine tissue. In MEN1 and MEN4, the mutated genes are tumor suppressors — their normal role is to brake uncontrolled cell division, and when both copies are lost ("two-hit" model), the brake is gone. In MEN2 (both 2A and 2B), the mutated gene is a proto-oncogene that is abnormally switched on, driving continuous cell proliferation. These different mechanisms explain why MEN2 syndromes tend to be more aggressive and present earlier than MEN1.

Living with a MEN diagnosis requires an ongoing partnership with specialists — endocrinologists, surgeons, and genetic counselors — at centers experienced in these rare syndromes. Surveillance is lifelong, and the management decisions are complex, involving the timing of prophylactic operations, the choice of surgical extent, and the monitoring of residual or recurrent disease.

Back to Table of Contents

MEN1 — Wermer's Syndrome

MEN1, first described by Paul Wermer in 1954, is caused by germline mutations in the MEN1 gene on chromosome 11q13. The MEN1 protein (menin) is a tumor suppressor that participates in chromatin remodeling, DNA repair, and transcriptional regulation. Like the classic model proposed by Alfred Knudson, a second somatic hit — a spontaneous mutation in the remaining wild-type allele within an individual cell — is required to initiate tumorigenesis. This "two-hit" mechanism explains why MEN1 patients develop tumors in multiple glands over time rather than all at once.

MEN1 is remembered by its three P's: Parathyroid, Pituitary, and Pancreatic/duodenal neuroendocrine tumors (NETs).

Parathyroid hyperplasia and adenoma affect approximately 90% of MEN1 patients, making it the most common and earliest manifestation — often appearing in the third decade of life. Unlike sporadic primary hyperparathyroidism, which typically involves a single adenoma, MEN1 almost always involves multiglandular disease affecting all four parathyroid glands to varying degrees. The resulting hypercalcemia causes symptoms familiar to clinicians as "bones, stones, groans, and psychic moans": osteoporosis with fracture risk, nephrolithiasis (kidney stones), constipation and nausea, and cognitive changes including depression and fatigue. Serum calcium and intact PTH are the primary screening tests, and abnormalities often precede other MEN1 manifestations by years.

Pituitary adenomas occur in 15 to 20% of MEN1 patients. Most are prolactinomas causing elevated prolactin, galactorrhea, and amenorrhea or erectile dysfunction. Non-functioning adenomas and those secreting growth hormone (causing acromegaly) or ACTH (causing Cushing's disease) are less common but clinically important. Annual prolactin screening plus periodic pituitary MRI form the core of pituitary surveillance.

Pancreatic and duodenal NETs occur in 40 to 70% of MEN1 patients and represent the major cause of MEN1-related mortality. The most clinically significant is gastrinoma, the hallmark of Zollinger-Ellison syndrome (ZES): autonomous gastrin secretion drives massive, unrelenting gastric acid production, causing peptic ulcers that resist standard doses of acid-suppressive therapy, and diarrhea. In MEN1, gastrinomas are typically multifocal and most often located in the duodenal wall rather than the pancreas. Diagnosis relies on fasting serum gastrin above 1000 pg/mL combined with an elevated basal acid output. High-dose proton pump inhibitors (PPIs) effectively control acid hypersecretion, and lifelong PPI therapy is standard. Insulinoma is the second most common symptomatic pancreatic NET in MEN1, causing fasting hypoglycemia with classic Whipple's triad (symptoms with low blood glucose, relief with glucose). Less common variants include glucagonoma (causing the necrolytic migratory erythema rash plus diabetes) and VIPoma (causing profuse watery diarrhea, hypokalemia, and achlorhydria — the WDHA syndrome).

Surveillance in MEN1 begins in childhood. Annual biochemical screening from age 5 includes serum calcium, PTH, prolactin, fasting gastrin, fasting glucose, and chromogranin A. Pancreatic MRI is recommended every one to three years to detect small NETs before they metastasize. Parathyroid surgery is typically indicated when hypercalcemia causes symptoms or when calcium significantly exceeds the upper limit of normal. The preferred approach is subtotal parathyroidectomy (removing 3.5 of 4 glands, leaving a small remnant) or total parathyroidectomy with autotransplantation of parathyroid tissue to the forearm — a site that allows easy access for re-excision if hyperparathyroidism recurs. Genetic testing of all first-degree relatives is essential at diagnosis.

Back to Table of Contents

MEN2A — Sipple's Syndrome

MEN2A, described by J.H. Sipple in 1961, is caused by activating germline mutations in the RET proto-oncogene on chromosome 10q11.2. Unlike MEN1 where menin is a brake on cell growth, RET normally encodes a receptor tyrosine kinase involved in the development of neural crest-derived cells. MEN2 mutations activate RET constitutively — the receptor is always "on," perpetually signaling cells to divide. The specific codon mutated in RET determines the aggressiveness of the syndrome, a relationship used clinically to time prophylactic surgery.

MEN2A has three components:

Medullary thyroid carcinoma (MTC) is present in virtually 100% of MEN2A patients, making it the defining feature. MTC arises from the parafollicular C cells of the thyroid, which normally secrete calcitonin to lower blood calcium. Because calcitonin is a highly sensitive and specific tumor marker for C-cell disease, serum calcitonin and CEA (carcinoembryonic antigen) serve both as screening tools and as post-operative surveillance markers. MTC in MEN2A is typically bilateral and multifocal, arising from C-cell hyperplasia — a premalignant predecessor detectable on pathology before frank carcinoma develops. Unlike papillary and follicular thyroid cancers, MTC does not respond to radioiodine because C cells do not take up iodine.

Pheochromocytoma occurs in approximately 50% of MEN2A patients. A critical safety principle governs all management decisions: pheochromocytoma must always be excluded biochemically before any thyroid or parathyroid surgery. An undiagnosed, unsecured pheo can release massive catecholamine surges in response to anesthetic induction, surgical manipulation, or positional changes, causing potentially fatal hypertensive crisis, arrhythmia, or cardiac arrest. Screening with plasma free metanephrines or 24-hour urine fractionated metanephrines is mandatory. In MEN2A, pheos are bilateral in approximately 50% of cases — a stark difference from sporadic pheos, which are bilateral in only 10%. Adrenal imaging (MRI preferred) confirms localization. Pheo is treated first, before thyroid surgery.

Primary hyperparathyroidism occurs in 20 to 30% of MEN2A patients. It tends to be milder than in MEN1 — single-gland disease is more common, and severe hypercalcemia is less typical. Many patients are identified only through biochemical surveillance rather than by symptoms.

The most important practical decision in MEN2A management is the timing of prophylactic thyroidectomy, guided by RET codon risk stratification established by the American Thyroid Association. Mutations are classified into three risk tiers. Highest risk mutations (such as codon 918 in MEN2B, less relevant here) call for thyroidectomy within six months of birth. High risk mutations including the most common MEN2A mutation at codon 634 — which confers the strongest pheo and parathyroid penetrance — warrant prophylactic thyroidectomy by age five, or earlier if calcitonin is rising. Moderate risk mutations can be followed biochemically with thyroidectomy deferred until calcitonin rises or until age five to ten. The goal of prophylactic thyroidectomy is to remove all C-cell tissue before malignant transformation, achieving biochemical cure.

Post-thyroidectomy surveillance includes calcitonin and CEA measurements every six months for the first year, then annually. A persistently detectable or rising calcitonin signals residual or recurrent disease and requires systematic imaging to locate the source.

Back to Table of Contents

MEN2B — Most Aggressive Form

MEN2B is the rarest (approximately 5% of all MEN2 cases) and most aggressive of the MEN syndromes. The overwhelming majority of MEN2B cases are caused by a single point mutation: codon 918 (M918T) in the RET kinase domain. This mutation produces a constitutively active RET receptor with the highest oncogenic potency of any RET alteration, explaining the distinctly earlier onset and more rapid progression of MTC in MEN2B compared to MEN2A.

MEN2B is recognized by a unique constellation of features beyond endocrine tumors:

Medullary thyroid carcinoma in MEN2B can develop in the first year of life and has been documented in neonates. Lymph node metastases may be present by age two or three if the diagnosis is delayed. This urgency drives the recommendation for prophylactic thyroidectomy in the first six months of life in infants confirmed to carry the codon 918 mutation. When thyroidectomy is performed before malignant transformation, biochemical cure is achievable; delayed diagnosis dramatically worsens prognosis.

Pheochromocytoma occurs in approximately 50% of MEN2B patients, with the same bilateral tendency and the same imperative to screen and treat pheo before thyroid or other surgery. The same pre-operative catecholamine screening and alpha-blockade protocol applies.

Mucosal neuromas are pathognomonic for MEN2B and are often the earliest visible sign — sometimes present at birth. They appear as small, fleshy, pink nodular bumps on the lips, anterior tongue, and conjunctiva, and as ganglioneuromas throughout the gastrointestinal tract. The bumpy, enlarged lips and nodular tongue give affected individuals a distinctive facial appearance that an alert clinician can recognize even before genetic testing. Recognizing this phenotype is clinically critical: it can prompt RET testing and thyroidectomy planning in an infant who has not yet had a genetic work-up.

Marfanoid habitus is present in most MEN2B patients: tall slender build, long limbs relative to trunk height, pectus excavatum or carinatum, joint hypermobility, and high arched palate. This body type resembles Marfan syndrome but without the cardiovascular features (aortic root dilation, lens dislocation) characteristic of true Marfan syndrome. The resemblance occasionally delays the correct MEN2B diagnosis.

Intestinal ganglioneuromatosis — proliferation of ganglion cells and nerve fibers throughout the GI tract — causes a range of motility problems including constipation, intermittent diarrhea, abdominal distension, and in severe cases megacolon requiring surgical intervention. These symptoms frequently appear in infancy or early childhood and may be the first clinical problem that leads a family to medical evaluation.

Notably, MEN2B does not include parathyroid disease. This distinguishes it cleanly from MEN2A and MEN1.

Because approximately 50% of MEN2B cases arise as de novo mutations rather than being inherited, a family history of MEN may be absent. Any infant or child presenting with mucosal neuromas, marfanoid features, or unexplained GI dysmotility should be considered for immediate RET mutation testing regardless of family history.

Back to Table of Contents

MEN4 and Other Variants

MEN4 is the most recently characterized MEN syndrome, first described in the early 2000s based on a rat model and subsequently confirmed in human patients. It is caused by germline mutations in CDKN1B, the gene encoding the cell cycle inhibitor p27Kip1. Like menin in MEN1, p27Kip1 normally restrains the cell cycle at the G1 checkpoint; loss of its function allows unregulated progression into DNA synthesis and cell division.

Clinically, MEN4 closely resembles MEN1. The predominant features are pituitary adenomas (most commonly non-functioning or ACTH-secreting) and primary hyperparathyroidism. Pancreatic NETs occur but appear to be less frequent and less aggressive than in MEN1. A handful of cases with additional features — including renal angiomyolipomas, meningiomas, and cervical carcinoma — have been reported, suggesting phenotypic variability.

MEN4 should be considered in patients who present with a MEN1-like clinical picture but in whom sequencing of the MEN1 gene is negative. It remains rare, with only a few hundred confirmed cases worldwide, and may be underdiagnosed because MEN1 gene testing has historically been the default in MEN1-like syndromes. Expanding genetic panels to include CDKN1B has improved detection rates.

Additional rare MEN-related conditions continue to be characterized. Familial isolated pituitary adenomas (FIPA) involves germline AIP mutations causing familial clusters of pituitary tumors, particularly somatotropinomas (growth hormone-secreting). DICER1 syndrome predisposes to a different spectrum including thyroid nodules, pleuropulmonary blastoma, and ovarian sex cord-stromal tumors. Carney complex (PRKAR1A mutations) combines cardiac and cutaneous myxomas with spotty skin pigmentation and multiple endocrine tumors including cortisol-producing adrenal nodules and pituitary adenomas. While not formally classified as MEN, these syndromes share the core principle: germline mutation driving tumor formation in multiple endocrine-related tissues, requiring lifelong surveillance and family testing.

The practical implication for the clinician is that any patient with two or more endocrine tumors, particularly at an age younger than expected for sporadic disease, should undergo comprehensive germline genetic panel testing — not just MEN1 and RET, but also CDKN1B, AIP, PRKAR1A, and DICER1 depending on the tumor phenotype — because incomplete testing delays diagnosis in rare syndrome carriers.

Back to Table of Contents

Genetic Testing and Counseling

Genetic testing is the cornerstone of MEN syndrome management. A molecular diagnosis enables risk stratification, guides surveillance intensity, and identifies which family members need evaluation — transforming a family-wide danger into a preventable condition for those found to carry the mutation.

For MEN1, testing involves sequencing the full MEN1 coding region plus analysis for large deletions and duplications, which account for approximately 10% of MEN1 mutations that would be missed by sequencing alone. For MEN2A and MEN2B, targeted analysis of the RET gene focuses on hotspot codons, with full sequencing reserved for cases where the phenotype is typical but no hotspot mutation is found. CDKN1B sequencing is indicated when MEN1 testing is negative in a MEN1-like presentation.

The RET genotype-phenotype correlation is particularly important and is used directly to determine the timing and urgency of prophylactic thyroidectomy. Codon 918 (M918T), the hallmark of MEN2B, dictates thyroidectomy within six months of birth. Codon 634 mutations, the most common MEN2A mutations, have the highest penetrance for pheo and parathyroid disease in addition to MTC, and carry a high-risk designation requiring thyroidectomy by age five. A table of codon-to-risk assignments is maintained in the ATA guidelines and should be consulted for each newly identified RET mutation.

Germline testing in children raises particular ethical considerations. The general consensus supports testing asymptomatic children when the result will directly guide medical management — as it does in MEN2, where a positive result triggers planning for life-altering prophylactic surgery in infancy or early childhood. Testing is deferred only when the result would not change management before the child reaches adulthood, as in some low-risk RET variants where surveillance may not begin until adolescence. Genetic counselors should be involved from the outset to ensure families understand the implications for life insurance, health insurance (in countries without mandated protections), psychological burden, and family relationships.

Next-generation sequencing (NGS) panels that simultaneously test multiple hereditary cancer genes are now widely available and cost-effective. They are particularly useful when the initial phenotype is incomplete or atypical, because a single test can evaluate MEN1, RET, CDKN1B, AIP, and related genes together. Variants of uncertain significance (VUS) in these genes require careful interpretation; clinical correlation and referral to specialized hereditary endocrine tumor programs is preferred over reactive management based on a VUS alone.

Cascade testing — systematic testing of all first-degree relatives of a newly diagnosed MEN patient — is the most impactful intervention in MEN syndrome management. In MEN2A families, for example, identifying a mutation carrier before calcitonin rises means prophylactic thyroidectomy can be performed electively at low risk, with an excellent chance of cure, rather than therapeutically after malignancy is established. The index patient's diagnosis is the starting point; the genetic counselor's cascade testing plan is what ultimately saves lives.

Back to Table of Contents

Screening Protocols

Lifelong biochemical and imaging surveillance is essential in all confirmed MEN mutation carriers, whether or not they have developed tumors yet. Surveillance protocols are tailored to each syndrome's tumor spectrum, and recommendations are periodically updated by specialty societies as evidence accumulates.

In MEN1, annual biochemical screening begins at age five and continues for life. The core panel includes:

Imaging in MEN1 uses MRI of the brain (pituitary focus) every three years or when prolactin rises, and MRI of the pancreas/abdomen every one to three years for pancreatic NETs. Small pancreatic NETs below 2 cm in asymptomatic MEN1 patients are often observed rather than resected, because the risk of surgery and the slow growth of many non-functional lesions may outweigh the benefit of early excision. This conservative approach differs from the management of symptomatic NETs or those growing on serial imaging.

In MEN2A and MEN2B carriers who have undergone prophylactic or therapeutic thyroidectomy, post-operative surveillance focuses on:

For MEN2 carriers who have not yet undergone thyroidectomy (awaiting planned prophylactic surgery or newly diagnosed adults), basal calcitonin is measured every six to twelve months. A stimulated calcitonin test (pentagastrin or calcium stimulation) can improve sensitivity for early C-cell hyperplasia, though pentagastrin availability varies by country.

Surveillance should be conducted by or in close consultation with endocrinologists, surgeons, and geneticists at specialized MEN centers. The rarity and complexity of these syndromes, combined with the high-stakes surgical decisions they require, makes general practitioner-only management suboptimal. Patient advocacy organizations such as the Endocrine Society's patient resources and dedicated MEN support groups are valuable adjuncts to clinical care, helping patients understand their diagnosis and navigate the surveillance schedule.

Back to Table of Contents

Treatment and Surgical Principles

Surgery is the primary treatment modality for most MEN-related tumors, but the principles governing MEN surgery differ in important ways from those for sporadic endocrine tumors. The multifocal nature of MEN disease, the high recurrence rates, and the interplay between tumors in different glands all require a nuanced approach tailored to the specific syndrome and the individual patient's circumstances.

Parathyroid surgery in MEN1 presents unique challenges. Because all four glands are at risk for hyperplasia or adenoma formation, the sporadic approach of removing the single abnormal gland is inadequate. The standard operations are:

Intraoperative PTH monitoring guides the extent of resection. Vitamin D and calcium supplementation is required post-operatively while the remaining or transplanted parathyroid tissue regains adequate function.

Pheochromocytoma is always treated before any other MEN-related surgery. Once biochemical evidence of catecholamine excess is confirmed, alpha-adrenergic blockade (typically phenoxybenzamine or doxazosin) is initiated for at least 10 to 14 days to normalize blood pressure and expand the contracted intravascular volume. Beta-blockade is added only after adequate alpha-blockade, to avoid unopposed alpha-stimulation causing severe hypertensive crisis. Laparoscopic adrenalectomy is the standard approach for most pheos, offering faster recovery and lower morbidity than open surgery.

In MEN2 patients with bilateral pheochromocytomas, cortical-sparing adrenalectomy (also called partial adrenalectomy) attempts to remove only the pheo-bearing medullary tissue while preserving functional adrenal cortex. When successful bilaterally, this avoids the need for lifelong steroid replacement therapy — a significant quality-of-life benefit and a safeguard against adrenal crisis during illness or surgery. The trade-off is a small but non-zero risk of pheo recurrence in the preserved cortical rim. Many MEN2 centers now favor cortical-sparing for bilateral pheos in young patients to avoid lifelong glucocorticoid and mineralocorticoid dependence.

Thyroidectomy for MTC requires total thyroidectomy with central neck lymph node dissection. The decision about lateral neck dissection depends on pre-operative calcitonin levels, ultrasound findings, and intraoperative findings. Post-operative calcitonin below the level of detection is the goal; detectable calcitonin after appropriately extensive surgery indicates residual disease. For locoregional recurrence, repeat surgery by an experienced thyroid surgeon is the preferred treatment when resectable.

Systemic therapy for progressive or metastatic MTC includes the tyrosine kinase inhibitors vandetanib and cabozantinib, both FDA-approved for symptomatic or progressive advanced MTC. These drugs inhibit RET kinase activity (among other targets) and produce measurable disease stabilization and partial responses, though complete responses are rare. Somatostatin analogues (octreotide, lanreotide) can control symptoms from functional pancreatic NETs in MEN1 (particularly VIPoma and glucagonoma) and may have antiproliferative effects. Everolimus (mTOR inhibitor) and sunitinib are approved for progressive pancreatic NETs and may be options in MEN1-related disease.

Across all MEN syndromes, the overarching surgical principle is that intervention should be appropriately aggressive in high-risk situations (rising calcitonin in a codon 634 carrier, biochemically confirmed pheo before any surgery) and thoughtfully conservative in lower-risk settings (asymptomatic small pancreatic NETs in MEN1, mild hypercalcemia in an elderly patient). Treatment decisions should be made by a multidisciplinary team — endocrinologist, endocrine surgeon, oncologist, radiologist, and genetic counselor — with input from experienced MEN centers when needed.

Back to Table of Contents

Research Papers

  1. Thakker RV, et al. (2012). Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab, 97(9):2990–3011. PMID 22723327. doi:10.1210/jc.2012-1230
  2. Wells SA Jr, et al. (2015). Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 25(6):567–610. PMID 25810047. doi:10.1089/thy.2014.0335
  3. Brandi ML, et al. (2001). Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab, 86(12):5658–5671. PMID 11739416. doi:10.1210/jcem.86.12.8070
  4. Kloos RT, et al. (2009). Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19(6):565–612. PMID 19469690. doi:10.1089/thy.2008.0403
  5. Lenders JW, et al. (2014). Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 99(6):1915–1942. PMID 24893135. doi:10.1210/jc.2014-1498
  6. Thakker RV. (2014). Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol, 386(1-2):2–15. PMID 23933118. doi:10.1016/j.mce.2013.08.002
  7. Carling T, Udelsman R. (2005). Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med, 257(1):27–37. PMID 15606371. doi:10.1111/j.1365-2796.2004.01429.x
  8. Machens A, et al. (2003). Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med, 349(16):1517–1525. PMID 14561795. doi:10.1056/NEJMoa012878
  9. Eng C. (1999). RET proto-oncogene in the development of human cancer. J Clin Oncol, 17(1):380–393. PMID 10458256. doi:10.1200/JCO.1999.17.1.380
  10. Lips CJ, et al. (1994). Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med, 331(13):828–835. PMID 8058073. doi:10.1056/NEJM199409293311302
  11. Dralle H, et al. (2008). Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery, 143(4):471–477. PMID 18374043. doi:10.1016/j.surg.2007.12.005
  12. Castinetti F, et al. (2019). Management of endocrine disease: pitfalls in the diagnosis of MEN1. Eur J Endocrinol, 180(1):R25–R36. PMID 30444697. doi:10.1530/EJE-18-0554

Search PubMed for more: multiple endocrine neoplasia MEN1 MEN2 RET germline | medullary thyroid carcinoma MEN2 prophylactic thyroidectomy | Zollinger-Ellison syndrome MEN1 gastrinoma

Back to Table of Contents

Connections

Back to Table of Contents